

Gabriele Calaminus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6173035/publications.pdf>

Version: 2024-02-01

41
papers

2,332
citations

471509

17
h-index

330143

37
g-index

44
all docs

44
docs citations

44
times ranked

3258
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1396-1408.	10.7	356
2	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019, 109, 36-50.	2.8	354
3	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2279-2287.	1.6	329
4	SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. <i>Neuro-Oncology</i> , 2013, 15, 788-796.	1.2	277
5	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
6	Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. <i>Neuro-Oncology</i> , 2017, 19, 1661-1672.	1.2	150
7	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
8	Pediatric Germ Cell Tumors From 1987 to 2011: Incidence Rates, Time Trends, and Survival. <i>Pediatrics</i> , 2015, 135, e136-e143.	2.1	62
9	ESGO—SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. <i>Lancet Oncology</i> , The, 2020, 21, e360-e368.	10.7	50
10	PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. <i>European Journal of Cancer</i> , 2018, 103, 227-237.	2.8	41
11	Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy. <i>International Journal of Cancer</i> , 2017, 141, 621-635.	5.1	40
12	Guidelines for Long-Term Follow-Up after Childhood Cancer: Practical Implications for the Daily Work. <i>Oncology Research and Treatment</i> , 2020, 43, 61-69.	1.2	38
13	CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms. <i>British Journal of Cancer</i> , 2020, 123, 378-391.	6.4	30
14	Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 119-127.	1.7	23
15	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. <i>Cancers</i> , 2020, 12, 611.	3.7	23
16	Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016). <i>Journal of Cancer Survivorship</i> , 2018, 12, 647-650.	2.9	21
17	The pioneer and differentiation factor FOXA2 is a key driver of yolk sac tumour formation and a new biomarker for paediatric and adult yolk sac tumours. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1394-1405.	3.6	21
18	Analysis of the adenomatous polyposis coli (APC) gene in childhood and adolescent germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2011, 56, 384-391.	1.5	18

#	ARTICLE	IF	CITATIONS
19	Brentuximab vedotin exerts profound antiproliferative and proapoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 568-575.	3.6	17
20	Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study. <i>Neuro-Oncology</i> , 2019, 21, 1069-1081.	1.2	16
21	Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28465.	1.5	15
22	ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 While ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition. <i>Cancers</i> , 2020, 12, 905.	3.7	15
23	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. <i>JAMA Oncology</i> , 2021, 7, 1550.	7.1	14
24	Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). <i>JMIR Research Protocols</i> , 2018, 7, e10824.	1.0	14
25	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. <i>BMC Cancer</i> , 2018, 18, 930.	2.6	13
26	Symptom interval and treatment burden for patients with malignant central nervous system germ cell tumours. <i>Archives of Disease in Childhood</i> , 2020, 105, 247-252.	1.9	12
27	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 1950-1961.	1.2	12
28	EPCAM—A novel molecular target for the treatment of pediatric and adult germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 24-32.	2.8	10
29	Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. <i>Neuro-Oncology Practice</i> , 2017, 4, 161-170.	1.6	9
30	Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. <i>JMIR Research Protocols</i> , 2021, 10, e21851.	1.0	9
31	MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 791-802.	2.5	9
32	Health outcomes in offspring born to survivors of childhood cancers following assisted reproductive technologies. <i>Journal of Cancer Survivorship</i> , 2021, 15, 259-272.	2.9	8
33	Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines. <i>Cancers</i> , 2020, 12, 1279.	3.7	5
34	Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. <i>JMIR Research Protocols</i> , 2019, 8, e14406.	1.0	4
35	Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. <i>Lancet Oncology</i> , The, 2022, 23, e218-e228.	10.7	4
36	Chromosomal gains of 12p and 1q are not associated with inferior outcome of pediatric and adolescent germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27777.	1.5	2

#	ARTICLE	IF	CITATIONS
37	HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials.. Neuro-Oncology, 2022, 24, i63-i64.	1.2	1
38	OR16-3 Posterior Hypothalamus-Sparing Surgery Improves Outcome after Childhood Craniopharyngioma: Results of the Prospective Multinational Trial Kraniopharyngeom 2007. Journal of the Endocrine Society, 2019, 3, .	0.2	0
39	The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.. Journal of Clinical Oncology, 2020, 38, 2503-2503.	1.6	0
40	GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. Neuro-Oncology, 2022, 24, i54-i54.	1.2	0
41	GCT-02. Imaging response assessment for Central Nervous System Germ Cell Tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group (SIOPE-BTG) and North American Children's Oncology Group (COG). Neuro-Oncology, 2022, 24, i53-i54.	1.2	0